Test Shows 26.1% Decrease in Plasma Lipid Oxidation

SCOTTSDALE, AZ, Oct. 6 /PRNewswire-FirstCall/ - Health Enhancement Products, Inc. (OTC BB: HEPI.OB - News, HEPI - News), in conjunction with Wayne State University (WSU) and the WSU research team, led by Smiti Gupta, Ph.D., assistant professor of nutrition & food sciences in the College of Liberal Arts and Sciences, have issued a positive preliminary report on lipid oxidation (oxidative stress) using HEPI's ProAlgaZyme (PAZ) filtrates.

Oxidative stress is defined as the tissue damage resulting from the imbalance between an excessive generation of oxidant compounds and antioxidant defense mechanisms. It is widely recognized that the generation of oxidative compounds is an important mechanism of normal physiology, playing a role in both inflammation and tissue repair processes. Oxidative stress represents part of the defense mechanisms against invading micro-organisms and malignant cells, as well as a signal for tissue healing and remodeling.

The test results show a statistically significant (p less than 0.050) decrease in plasma lipid peroxidation value of 9.6 nMol/ml for a group of animals drinking PAZ filtrates compared to 13.0 nMol/ml for a control group which was administered pure drinking water, a 26.1% decrease. The results are part of the long-term study being conducted by Dr. Gupta's research team based at WSU. These results follow the Company's July 15, 2009 announcement disclosing preliminary test results which indicated that the PAZ organic compound reduced LDL cholesterol levels from 132 mg/dL to 80 mg/dL and improved HDL cholesterol from 105 mg/dL to 139 mg/dL in test animal subjects.

Dr. Gupta commented, "The test results showed a significant decrease in plasma lipid peroxidation values in a test group of animals administered ProAlgaZyme filtrate in their drinking water as compared to the control group given pure water," states Dr. Gupta. "This in conjunction with the previously reported decrease in total cholesterol and simultaneous increase in the HDL cholesterol, points to the potential benefits of Proalgazyme filtrates. In addition, oxidative stress has been linked with inflammation in general, an area of inquiry that we are pursuing further."

Health Enhancement Products, Inc. Interim CEO Peter Vitulli, stated, "Today's significant results in lowering oxidized lipids in plasma of test animal subjects marks yet another impressive result of the PAZ Compound. As most people have become keenly aware, oxidative stress, if left unchecked has been linked to a wide variety of conditions and impairments in the human body."

Mr. Vitulli continued, "As we have previously mentioned, as a result of the initial success of the study, we have expanded its reach and have contacted outside organizations to perform further tests which are being executed. As we close in on identifying the active agent(s) of the PAZ compound, we have also begun to explore the most effective ways to maximize the use of PAZ for various industries and business segments. We hope to provide additional details in the near future."

About Health Enhancement Products, Inc.

Health Enhancement Products, Inc. (OTC BB: HEPI - News) is a health & wellness company engaged in the development of dietary supplements and food additives comprised of pure, all-natural compounds. The Company's product is ProAlgaZyme (PAZ), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled as ProAlgaZyme.

About Wayne State University

Wayne State University is one of the nation's pre-eminent public research universities in an urban setting. Through its multidisciplinary approach to research and education, and its ongoing collaboration with government, industry and other institutions, the university seeks to enhance economic growth and improve the quality of life in the city of Detroit, state of Michigan and throughout the world. For more information about research at Wayne State University, visit http://www.research.wayne.edu.

Safe Harbor Statement

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, final test results being different from preliminary test results, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

CONTACT: Health Enhancement Products, Inc., John Gorman, Director of Sales, (480) 385-3800, john@heponline.com; IR Contact: Howard Gostfrand, David Sasso, (305) 918-7000, info@amcapventures.com, www.amcapventures.com; WSU Contact: Julie O'Connor, (313) 577-8845, ag2712@wayne.edu, www.research.wayne.edu